anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A molecular subgroup of cancer is characterised by misregulation of the MAPK signalling pathway and the epithelial-mesenchymal transition (EMT) pathway. Biomarker signatures can be used to identify cancers within the molecular subgroup. The signatures are also useful for identifying the treatment that is best suited for a given patient. A method for selecting a treatment for a subject having a cancer, comprises measuring the expression level(s) of at least biomarker selected from Table A or Table B in a sample from the subject. By assessing the expression level(s) of the at least 1 biomarker it can be determined whether the sample from the subject is positive or negative for a biomarker signature comprising the at least 1 biomarker. Based on the outcome of this assessment different treatments selected from MAPK pathway 10 inhibitors, EMT pathway inhibitors, SRC pathway inhibitors, taxanes and anti-angiogenic therapeutic agents may be indicated. Related treatment methods and products are also provided.
NEW MATERIAL:The bis-dioxopiperazine derivative of formula I (R is alkyl, cycloalkyl, halogenated alkyl, carboxyalkyl, aryloxyalkyl, aralkkyl, arylalkenyl, aryl, heterocyclic group or alkoxy) or its salt. EXAMPLE:1,2-Bis(4-acetoxymethyl-3,5-dioxopiperazin-1-yl)-ethane. USE:An antitumor agent. It has broad antitumor activity and metasasis-suppressing activity, high stability to a protonic polar solvent suitable for the drug preparation, and low toxicity. PREPARATION:The compound of formula I is produced by reacting the novel compound of formula II with the reactive derivative of the compound of formula III. The novel compound of formula II can be obtained easily by reacting 1,2- bis(3,5-dioxopiperazin-1-yl)-ethane with formaldehyde.
Recent research has highlighted the role of complement genes in shaping the microstructure of the brain during early development, and in contributing to common allele risk for Schizophrenia. We hypothesised that common risk variants for schizophrenia within complement genes will associate with structural changes in white matter microstructure within tracts innervating the frontal lobe. Results showed that risk alleles within the complement gene set, but also intergenic alleles, significantly predict axonal density in white matter tracts connecting frontal cortex with parietal, temporal and occipital cortices. Specifically, risk alleles within the Major Histocompatibility Complex region in chromosome 6 appeared to drive these associations. No significant associations were found for the orientation dispersion index. These results suggest that changes in axonal packing - but not in axonal coherence - determined by common risk alleles within the MHC genomic region - including variants related to the Complement system - appear as a potential neurobiological mechanism for schizophrenia.
The invention relates to a preparation method of turtle and snake liquor. Rheumatism is a very common chronic disease in people's life, the diseased population is mostly senior citizens, and the symptoms of rheumatism bring substantial pains to patients but are hard to be cured. The patent relates to turtle and snake liquor, which, through oral administration and external application, has an obvious effect on rheumatism. The preparation method comprises: adding water to Xiangyuan rice and conducting fermentation distillation so as to obtain liquor; adding cockchafers and ophiophagus hannah to immerse for 6 months, then adding Chinese angelica, Chinese wolfberries and eucommia for dipping; and finally dissolving rock sugar in the liquor. The turtle and snake liquor of the invention can be drunk for 30 milliliters on an empty stomach in the morning and evening. And while the illness occurred, the liquor provided in the invention can be applied to a suffering part and can reach an illness alleviating effect.
PROBLEM TO BE SOLVED: To prepare a medicine-containing fat emulsion capable of improving the retentivity of the medicine in blood. SOLUTION: This medicine-containing fat emulsion comprises the medicine, an oily ingredient, an emulsifying agent and water. The emulsifying agent is a phospholipid having <=5 iodine value and a hydrogenated egg yolk lecithin or soybean lecithin is cited. A phospholipid in which all of the fatty acid residues thereof are saturated fatty acid residues, preferably a glycerophospholipid of formula I or II, etc., (R<1> and R<2> are each a saturated fatty acid residue) is further cited. The amounts of the blended ingredients based on the fat emulsion are 0.01-10% (wt./vol.) phospholipid and 1-50%(wt./vol.) oily ingredient (e.g. soybean oil). The fat emulsion is preferably administered by injection, continuous drip infusion. etc., and intravenous administration is especially preferred.  A triacylglycerol which is a core part of fat particles hardly undergoes hydrolysis with a lipoprotein lipase, etc., and the fat emulsion is excellent in retentivity of the medicine in blood to sustain efficacies of the medicine.
The invention discloses a polypeptide inhibitor for inhibiting ten kinds of coronavirus. Belongs to the technical field of biological medicine. The polypeptide inhibitor comprises: 1) an amino acid sequence shown as SEQ ID No. 1; or, 2) a sequence which is obtained by replacing, adding and/or deleting one or more amino groups in the amino acid sequence shown in SEQ ID No.1 and is derived from the sequence shown in SEQ ID No.1 and has the same function; or 3) a core sequence of the sequence shown in SEQ ID No.1, wherein the core sequence is SEQ ID No. 2. The polypeptide inhibitor has extremely high broad spectrum and can inhibit ten different coronaviruses simultaneously, so that the polypeptide inhibitor can rapidly and timely respond to infectious respiratory diseases caused by a certain unknown novel coronaviruses at an uncertain time point in the future at the first time, and the defect that the existing single treatment medicament has large side effect and is easy to cause sequelae is overcome.
Retinal toxicity

Risdiplam-induced functional and structural retinal abnormalities were seen in animal studies. In a 39-week toxicity study in monkeys, oral administration of risdiplam (0, 1.5, 3, or 7.5/5 mg/kg/day; high dose lowered after 4 weeks) produced functional abnormalities on the electroretinogram (ERG) in all mid- and high-dose animals at the earliest examination time (Week 20). These findings were associated with retinal degeneration, detected by optical coherence tomography (OCT), on Week 22, the first examination time. The retinal degeneration, with peripheral photoreceptor loss, was irreversible. A no-effect dose for the retinal findings (1.5 mg/kg/day) was associated with plasma exposures (AUC) similar to that in humans at the maximum recommended human dose (MRHD) of 5 mg.

Effect on Epithelial Tissues

Oral administration of risdiplam to rats and monkeys resulted in histopathological changes in epithelium of the gastrointestinal (GI) tract (apoptosis/single cell necrosis), lamina propria (vacuolation), the exocrine pancreas (single cell necrosis), the skin, tongue, and larynx (parakeratosis/hyperplasia/degeneration) with associated inflammation. The skin and GI epithelial effects were reversible. The no-effect doses for effects on epithelial tissues in rats and monkeys were associated with plasma exposures (AUC) similar to that in humans at the MRHD.
Athletes increasingly engage in repeated sprint training consisting in repeated short all-out efforts interspersed by short recoveries. When performed in hypoxia (RSH), it may lead to greater training effects than in normoxia (RSN); however, the underlying molecular mechanisms remain unclear. This study aimed at elucidating the effects of RSH on skeletal muscle metabolic adaptations as compared to RSN. Sixteen healthy young men performed nine repeated sprint training sessions in either normoxia (FIO2 = 0.209, RSN, n = 7) or normobaric hypoxia (FIO2 = 0.136, RSH, n = 9). Before and after the training period, exercise performance was assessed by using repeated sprint ability (RSA) and Wingate tests. Vastus lateralis muscle biopsies were performed to investigate muscle metabolic adaptations using proteomics combined with western blot analysis. Similar improvements were observed in RSA and Wingate tests in both RSN and RSH groups. At the muscle level, RSN and RSH reduced oxidative phosphorylation protein content but triggered an increase in mitochondrial biogenesis proteins. Proteomics showed an increase in several S100A family proteins in the RSH group, among which S100A13 most strongly. We confirmed a significant increase in S100A13 protein by western blot in RSH, which was associated with increased Akt phosphorylation and its downstream targets regulating protein synthesis. Altogether our data indicate that RSH may activate an S100A/Akt pathway to trigger specific adaptations as compared to RSN.
PURPOSE:To apply beautiful luster to the surface of a tablet with simple operation irrespective of the surface smoothness of the sugar-coated tablet, by mixing sugar-coated tablets in fluidized state with a polishing agent composed of a solid wax for polishing and a lubricant. CONSTITUTION:A polishing agent is produced by mixing a solid wax for polishing (e.g. beeswax, paraffin or carnauba wax) with a lubricant (e.g. talc, magnesium stearate or synthetic aluminum silicate) at a weight ratio of 9:1-1:9. The obtained polishing agent is mixed with sugar-coated tablets in fluidized state. The uneven surface of the sugar-coated tablet is polished and smoothened and the coagulation of the solid wax can be prevented by the mixing of the lubricant.
A pellet for administration to ruminants (see Division A5) comprises a magnesium alloy containing the following elements in addition to magnesium: .Co.0 to 0.5% .Al.0 to 15% .Zn.0 to 5% .Cu.0 to 5% .Ni.0 to 1% The pellet may also contain iron powder or shot, steel powder, or iron oxide, zinc oxide, zirconium oxide or zirconium silicate powder.ALSO:A pellet for oral administration to ruminants comprises magnesium or a magnesium alloy and a particulate substance, e.g. iron powder or shot, iron oxide, zirconium oxide, zirconium silicate or zinc oxide in such proportions that the S.G. is at least 2.2. Various embodiments are described including wholly and partly coated pellets in which the particulate material is distributed throughout the alloy or is present in a core.  Other therapeutic agents, e.g. an antibiotic, may also be present.ALSO:A pellet for oral administration to ruminants comprises magnesium or magnesium alloy and a particulate substance, e.g. iron powder or shot, iron oxide, zirconium oxide, zirconium silicate or zinc oxide in such proportions that its specific gravity is at least 2.2.  Various embodiments are described including partly and wholly coated pellets in which the particulate material is distributed throughout the alloy or is present as a "core" or core-constituent.  Other therapeutic ingredients, e.g. an antibiotic, may also be present.
Participants will receive simtuzumab IV every other week for a total of 3 infusions. The dose will depend on the safety and tolerability of simtuzumab seen in Cohort 1 but will not exceed 20 mg/kg.
PURPOSE:A skin external agent, obtained by incorporating a granule granulated by an oil-resistant binder with other components, and having improved washing or massage effect and further improved feeling of satisfaction after use. CONSTITUTION:A skin external agent obtained by sprinkling an oil-resistant binder which is a water-soluble high polymer such as hydroxyethyl cellulose, methyl cellulose, carboxymethyl cellulose, polyvinyl alcohol, gelatin, sodium alginate or polyacrylic acid derivative as an aqueous solution on powder having <=0.1mm. particle size of an inorganic pigment, e.g. talc or titanium oxide, or high polymer material, e.g. polyamide such as nylon, which is stirred in a fluidized granulator or stirred granulator by a method, e.g. spraying, to granulate the powder, and produce granule having 0.05-2.0mm. grain diameter, and incorporating 0.1-50wt% resultant granule in a water-in-oil type (W/O) system or oil system in a skin external agent in the form of cream or gel.
The invention relates to the field of biological pharmacy, in particular to application of a monoclonal antibody or an antigen binding fragment thereof with 3 heavy chain CDR sequences of SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3 and/or 3 light chain CDR sequences of SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6 in preparation of a medicament for treating specific solid tumor subtypes, cervical cancer subtypes, mesothelioma, lymphoma or non-small cell lung cancer; in another aspect, the present invention provides a method of treatment for the solid tumors described above.
Accumulating evidence supports the notion that microglia play versatile roles in different chronic pain conditions. However, therapeutic strategies of chronic pain by targeting microglia remain largely overlooked. This study seeks to develop a miRNA-loaded nano-delivery system by targeting microglia, which could provide a decent and long-lasting analgesia for chronic pain. Surface aminated mesoporous silica nanoparticles were adopted to load miR-26a-5p, a potent analgesic miRNA, by electrostatic adsorption, which can avoid miR-26a-5p is rapidly released and degraded. Then, targeting peptide MG1 was modified on the surface of aminated mesoporous silica particles for microglia targeting. In peripheral nerve injury induced neuropathic pain model, a satisfactory anti-allodynia effect with about 6 weeks pain-relief duration were achieved through targeting microglia strategy, which decreased microglia activation and inflammation by Wnt5a, a non-canonical Wnt pathway. In inflammatory pain and chemotherapy induced peripheral neuropathic pain, microglia targeting strategy also exhibited more efficient analgesia and longer pain-relief duration than others. Overall, we developed a microglia-targeting nano-delivery system, which facilitates precisely miR-26a-5p delivery to enhance analgesic effect and duration for several chronic pain conditions.
Dextrose Injection 5%, USP is a clear, sterile solution of dextrose supplied in single-dose, flexible containers. The product is available as quad packs (4 units per overpouch). Table 2 lists quad pack presentation compatible with vials with a 13 mm closure, and Table 3 lists quad pack presentation compatible with vials with a 20 mm closure.

Do not remove container from the overwrap until intended for use.

Minimize exposure of Dextrose Injection to heat. Avoid excessive heat. Store at room temperature (25°C/77°F).
PURPOSE:To provide a highly functional skin flexibilizer having quickly effective, sustainable excellent flexibilizing effect compatible with favorable feel after use, useful for keeping the skin fresh through preventing the development or increase of wrinkles due to stratum corneum brittleness. CONSTITUTION:The objective skin flexibilizer comprising (A) an oleic acid derivative <=4000 in molecular weight of formula (HO)n-A-(OR)m (R is acyl of oleic acid >=85wt.% in the purity of cis-DELTA9-octadecenoic acid; A is saturated or unsaturated hydrocarbon group, ether linkage-contg. saturated or unsaturated hydrocarbon group or saturated or unsaturated hydrocarbon group partly containing F atoms in place of H atoms; m is 1-12; n is 0-2; (m+n) is 1-12) and (B) a humectant at the weight ratio B/A of (0.0001-0.5), pref. (0.001-0.2). The component A is e.g. ethyl oleate, glycerol trioleate, 1,1,2,2- tetrahydroheptadecafluorodecanol oleate.
FIELD: biotechnology, biochemistry, medicine. SUBSTANCE: invention relates to methods of synthesis of substances with bifunctional and multifunctional biological activity. Invention relates to method of preparing soluble conjugates of biologically active substances involving coupling protein with dextran used as polysaccharide carrier. Proteins of different functional activity are coupled with dextran. Enzyme peroxidase and detector proteins used for assay of immunoglobulins can be coupled with dextran where fractions IgG or Staphylococcus aureus protein A, or streptococcus protein G can be used as detector proteins for assay of immunoglobulins. The best results are obtained in the molar ratio of components to be coupled dextran : detector protein : peroxidase = (1:5:5):(1:5:10). EFFECT: expanded assortment of immunocompetent agents of technology. 12 cl, 7 tbl
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that has a complex genetic basis. Through advancements in genetic screening, researchers have identified more than 40 mutant genes associated with ALS, some of which impact immune function. Neuroinflammation, with abnormal activation of immune cells and excessive production of inflammatory cytokines in the central nervous system, significantly contributes to the pathophysiology of ALS. In this review, we examine recent evidence on the involvement of ALS-associated mutant genes in immune dysregulation, with a specific focus on the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway and N6-methyladenosine (m6A)-mediated immune regulation in the context of neurodegeneration. We also discuss the perturbation of immune cell homeostasis in both the central nervous system and peripheral tissues in ALS. Furthermore, we explore the advancements made in the emerging genetic and cell-based therapies for ALS. This review underscores the complex relationship between ALS and neuroinflammation, highlighting the potential to identify modifiable factors for therapeutic intervention. A deeper understanding of the connection between neuroinflammation and the risk of ALS is crucial for advancing effective treatments for this debilitating disorder.
Patients undergoing arthroscopic knee surgery (ACL and non-ACL surgery) typically receive an ultrasound-guided femoral nerve block or an adductor canal block in the pre-operative phase for post-operative pain control. While an effective method for post-operative analgesia, the femoral nerve block is associated with profound quadriceps weakness for the duration of the nerve block, which can impair ambulation, rehabilitation, and increase the risk of falls. The more distal adductor canal block, however, contains primarily sensory branches of the femoral nerve and has been been purported by small volunteer studies to provide equally effective analgesia with minimal motor block and quadriceps weakness (as compared to femoral nerve block).

The investigators will prospectively randomize patients undergoing knee arthroscopy at the UCSF Orthopaedic Institute to receive either a single-shot femoral nerve or adductor canal block pre-operatively after taking baseline measurements of quadriceps strength (quantified by maximum voluntary isometric contraction). The quadriceps muscle strength will be checked 20 minutes after the nerve block to assess strength. All patients will subsequently undergo a general anesthetic. The primary outcome variable will be post-block quadriceps strength as a percentage of baseline from pre-block values. Secondary outcome variables that will also investigated include: VAS pain score in the post anesthesia recovery unit and post-operative day 1, time to onset of sensory block, duration of nerve blockade, block performance time, patient satisfaction score, perioperative opioid use, perioperative analgesic consumption, incidence of paresthesias, number of needle passes, incidence of post-operative nausea, vomiting, constipation, and any other complications.
Anti-aging and tumorigenesis share common genes and pathways, and thus targeting these genes as part of anti-aging interventions carries the risk of tumorigenesis. It is essential to understand the gene signatures that balance tumorigenesis and aging. To achieve this goal, we analyzed RNA-sequencing data from three non-tumorigenic immortalized cell lines that spontaneously escaped from senescence. By single sample gene set enrichment assay (ssGSEA) and GSEA analysis, we found that both cell growth signaling (E2F targets, MYC targets) and tumor surveillance mechanisms (DNA repair, G2M checkpoint, mitotic spindle) were up-regulated in all three cell lines, suggesting that these genes are potential signatures for non-tumorigenic immortalization. Further analysis revealed that the 182 commonly up-regulated genes in these three cell lines overlapped with the DREAM/G2M pathway, which is known to be the upstream regulator of E2F, Myc targets, DNA repair, G2M checkpoint and mitotic spindle pathways in its cell cycle activation or inhibitory form. By western blotting, quantitative PCR and co-immunoprecipitation, we verified that both forms of the DREAM pathway are up-regulated in all three cell lines; this pathway facilitates control of cell cycle progression, supporting a new mechanism for non-tumorigenic immortalization. Thus, we propose that the DREAM/G2M pathway plays important dual roles with respect to preventing tumorigenesis in the process of immortalization. Our data might serve as the basis for the identification of new signature pathways or gene biomarkers for non-tumorigenic immortalization, and may aid in the discovery of new targets for tumor-free anti-aging drug screening.
In this study, the postoperative cognitive dysfunction (POCD) mouse model was established to observe the changes in inflammation, blood-brain barrier permeability, and myelin sheath, and we explore the effect of ginsenoside Rg1 pretreatment on improving POCD syndrome. The POCD model of 15- to 18-month-old mice was carried out with internal fixation of tibial fractures under isoflurane anesthesia. Pretreatment was performed by continuous intraperitoneal injection of ginsenoside Rg1(40 mg/kg/day) for 14 days before surgery. The cognitive function was detected by the Morris water maze. The contents of interleukin-1β and tumor necrosis factor-α in the hippocampus, cortex, and serum were detected by ELISA. The permeability of blood-brain barrier was observed by Evans blue. The mRNA levels and protein expression levels of 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase), myelin basic protein (MBP), beta-catenin, and cyclin D1 in the hippocampus were analyzed by quantitative PCR and western blotting. The protein expression levels of ZO-1 and Wnt1 in the hippocampus were analyzed by western blotting. Finally, the localizations of CNPase and MBP in the hippocampus were detected by immunofluorescence. Ginsenoside Rg1 can prevent POCD, peripheral and central inflammation, and blood-brain barrier leakage, and reverse the downregulation of ZO-1, CNPase, MBP, and Wnt pathway-related molecules in aged mice. Preclinical studies suggest that ginsenoside Rg1 improves postoperative cognitive function in aged mice by protecting the blood-brain barrier and myelin sheath, and its specific mechanism may be related to the Wnt/β-catenin pathway.